Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
- PMID: 35176090
- PMCID: PMC8853550
- DOI: 10.1371/journal.ppat.1010260
Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously evolving, and this poses a major threat to antibody therapies and currently authorized Coronavirus Disease 2019 (COVID-19) vaccines. It is therefore of utmost importance to investigate and predict the putative mutations on the spike protein that confer immune evasion. Antibodies are key components of the human immune system's response to SARS-CoV-2, and the spike protein is a prime target of neutralizing antibodies (nAbs) as it plays critical roles in host cell recognition, fusion, and virus entry. The potency of therapeutic antibodies and vaccines partly depends on how readily the virus can escape neutralization. Recent structural and functional studies have mapped the epitope landscape of nAbs on the spike protein, which illustrates the footprints of several nAbs and the site of escape mutations. In this review, we discuss (1) the emerging SARS-CoV-2 variants; (2) the structural basis for antibody-mediated neutralization of SARS-CoV-2 and nAb classification; and (3) identification of the RBD escape mutations for several antibodies that resist antibody binding and neutralization. These escape maps are a valuable tool to predict SARS-CoV-2 fitness, and in conjunction with the structures of the spike-nAb complex, they can be utilized to facilitate the rational design of escape-resistant antibody therapeutics and vaccines.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
![Fig 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8853550/bin/ppat.1010260.g001.gif)
![Fig 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8853550/bin/ppat.1010260.g002.gif)
![Fig 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8853550/bin/ppat.1010260.g003.gif)
![Fig 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8853550/bin/ppat.1010260.g004.gif)
![Fig 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8853550/bin/ppat.1010260.g005.gif)
![Fig 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8853550/bin/ppat.1010260.g006.gif)
Similar articles
-
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.Genome Med. 2021 Oct 14;13(1):164. doi: 10.1186/s13073-021-00985-w. Genome Med. 2021. PMID: 34649620 Free PMC article.
-
Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.Eur Rev Med Pharmacol Sci. 2021 Sep;25(18):5857-5864. doi: 10.26355/eurrev_202109_26805. Eur Rev Med Pharmacol Sci. 2021. PMID: 34604978 Review.
-
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421. Viruses. 2021. PMID: 34452287 Free PMC article.
-
A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.Front Immunol. 2021 Apr 28;12:647934. doi: 10.3389/fimmu.2021.647934. eCollection 2021. Front Immunol. 2021. PMID: 33995366 Free PMC article. Review.
-
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312. Elife. 2020. PMID: 33112236 Free PMC article.
Cited by
-
Carrimycin inhibits coronavirus replication by decreasing the efficiency of programmed -1 ribosomal frameshifting through directly binding to the RNA pseudoknot of viral frameshift-stimulatory element.Acta Pharm Sin B. 2024 Jun;14(6):2567-2580. doi: 10.1016/j.apsb.2024.02.023. Epub 2024 Mar 3. Acta Pharm Sin B. 2024. PMID: 38828157 Free PMC article.
-
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines.Drugs. 2024 Apr;84(4):403-423. doi: 10.1007/s40265-024-02013-8. Epub 2024 Apr 23. Drugs. 2024. PMID: 38652356 Review.
-
Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy.Pharmacol Rep. 2024 Apr;76(2):307-327. doi: 10.1007/s43440-024-00585-6. Epub 2024 Mar 18. Pharmacol Rep. 2024. PMID: 38498260 Review.
-
Generation of a humanized mAce2 and a conditional hACE2 mouse models permissive to SARS-COV-2 infection.Mamm Genome. 2024 Jun;35(2):113-121. doi: 10.1007/s00335-024-10033-8. Epub 2024 Mar 15. Mamm Genome. 2024. PMID: 38488938
-
Event rates and incidence of post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID).BMC Med. 2024 Feb 1;22(1):48. doi: 10.1186/s12916-023-03221-x. BMC Med. 2024. PMID: 38302974 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous